Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) has announced the results of a preclinical study of its lead compound, Telomir-1, conducted in an animal model of Werner Syndrome, a rare genetic disorder that causes premature aging. The study demonstrated that Telomir-1 effectively reset key biological aging markers, including DNA methylation, and restored healthy gene regulation. Notable findings included a significant increase in telomere length, a full reversal of muscle and body weight loss, up to a 50% reduction in oxidative stress markers, and 100% survival in treated animals compared to a 15% mortality rate in untreated controls. These results suggest that Telomir-1 may have potential as a therapeutic candidate for aging-related diseases. Telomir Pharmaceuticals plans to continue the development of Telomir-1, focusing on addressing mechanisms related to telomere dysfunction and epigenetic instability.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.